Premium Nahrungsergänzungsmittel | artgerecht

TIM-3 Signaling Pathway – Immune Checkpoint Explained

The TIM-3 signaling pathway is an immunoregulatory mechanism that promotes T cell exhaustion and plays a key role in tumor immune evasion and chronic infections.

Regular tips about health Regular tips about health

Things worth knowing about "TIM-3 signaling pathway"

The TIM-3 signaling pathway is an immunoregulatory mechanism that promotes T cell exhaustion and plays a key role in tumor immune evasion and chronic infections.

What is the TIM-3 Signaling Pathway?

The TIM-3 signaling pathway (T-cell Immunoglobulin and Mucin Domain-3) is a major immunoregulatory pathway that controls the behavior of immune cells – particularly T lymphocytes. TIM-3 is an inhibitory receptor, also referred to as an immune checkpoint, that is expressed on the surface of exhausted T cells, natural killer (NK) cells, dendritic cells, and macrophages.

In simple terms, TIM-3 acts as a “brake” on the immune system: when activated, it dampens the immune response and prevents excessive inflammation. However, in certain disease states – such as cancer or chronic infections – this mechanism is exploited to permanently suppress immune cells.

Ligands and Activation

The TIM-3 signaling pathway is activated by the binding of specific ligands to the TIM-3 receptor. The most important ligands include:

Galectin-9: A lectin that is increasingly secreted during inflammatory responses and initiates apoptosis (programmed cell death) of Th1 cells.
HMGB1 (High Mobility Group Box 1): An alarmin released during tissue damage that modulates the innate immune response.
CEACAM1 (Carcinoembryonic Antigen-related Cell Adhesion Molecule 1): Co-expressed with TIM-3 on T cells and enhances its inhibitory function.
Phosphatidylserine: A lipid on apoptotic cells that promotes phagocytic clearance.

Mechanism of Action

Upon ligand binding to TIM-3, intracellular signaling cascades are triggered that inhibit T cell activation and proliferation. The pathway closely interacts with the PD-1/PD-L1 checkpoint and reinforces the state of T cell exhaustion – a condition in which T cells lose their effector functions (e.g., cytokine production, cytotoxicity).

At the molecular level, TIM-3 activation inhibits the NF-κB signaling pathway and the production of pro-inflammatory cytokines such as IFN-γ (interferon-gamma) and TNF-α (tumor necrosis factor-alpha). In addition, the mTOR signaling cascade is affected, altering T cell metabolism and survival.

Clinical Significance

Tumor Immunology

In oncology, TIM-3 is of particular importance. Tumors create an immunosuppressive microenvironment in which TIM-3 is strongly upregulated on tumor-infiltrating lymphocytes (TILs), leading to T cell exhaustion and enabling tumor cells to escape immune surveillance. TIM-3 is overexpressed in various tumor types, including:

Melanoma
Non-small cell lung cancer (NSCLC)
Acute myeloid leukemia (AML)
Colorectal carcinoma
Hepatocellular carcinoma (liver cancer)

Chronic Infections

In chronic viral infections such as HIV, Hepatitis B, and Hepatitis C, TIM-3 is upregulated on exhausted virus-specific T cells. Persistent antigen exposure leads to progressive T cell dysfunction, which is co-regulated by TIM-3.

Autoimmune Diseases

Paradoxically, reduced TIM-3 activity may increase the risk of autoimmune diseases. Since TIM-3 normally dampens immune responses, a dysfunction in this pathway can lead to uncontrolled inflammatory reactions, as observed in multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus (SLE).

Therapeutic Approaches

The TIM-3 signaling pathway is a promising target for immune checkpoint immunotherapy. Several anti-TIM-3 antibodies (TIM-3 inhibitors) are currently being investigated in clinical trials:

Sabatolimab (MBG453): Studied in combination with other checkpoint inhibitors or chemotherapy in clinical trials for AML and myelodysplastic syndrome (MDS).
Cobolimab (TSR-022): Being investigated in combination with anti-PD-1 therapies in various solid tumors.
LY3321367: Another anti-TIM-3 antibody in early clinical phases.

Combining TIM-3 inhibitors with existing immune checkpoint blockades (e.g., anti-PD-1 or anti-CTLA-4) is intended to create synergistic effects and enhance the efficacy of cancer immunotherapy, particularly in patients who do not respond to PD-1/PD-L1 blockade alone.

Summary

The TIM-3 signaling pathway is a central immune checkpoint mechanism that regulates the balance between immune activation and tolerance. Its overactivation promotes T cell exhaustion and tumor evasion, while its inhibition opens new opportunities for cancer immunotherapy. Ongoing research into TIM-3 inhibitors shows great potential for the treatment of cancer, chronic infections, and autoimmune diseases.

References

Anderson, A.C. et al. (2016): TIM-3: An inhibitory receptor implicated in tumor immunity and exhaustion. Immunity, 44(5), 989–1004. doi:10.1016/j.immuni.2016.05.003
Wolf, Y., Anderson, A.C., Bhatt, D.L. (2020): TIM-3 comes of age as an inhibitory receptor. Nature Reviews Immunology, 20(3), 173–185. doi:10.1038/s41577-019-0224-6
Shayan, G. et al. (2017): Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology, 6(1), e1261779. doi:10.1080/2162402X.2016.1261779

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.